Clinical Trials Logo

Overactive Bladder Syndrome clinical trials

View clinical trials related to Overactive Bladder Syndrome.

Filter by:

NCT ID: NCT05792956 Enrolling by invitation - Clinical trials for Overactive Bladder Syndrome

Mobile Application and Bladder Training

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The International Continence Society described overactive bladder as urine urgency, frequently accompanied by frequency and nocturia, with or without urgency incontinence, when there is no evident pathology, such as a urinary tract infection. According to studies in the literature, women who have overactive bladders experience negative effects on their sexual satisfaction and quality of life. According to a study by Juliato et al. (2017), women with more severe urinary symptoms experienced higher degrees of arousal, lubrication, orgasm, and discomfort. According to Chuang et al. (2017) study, women's sexual pleasure and quality of life declined as urinary symptom intensity increased. It is believed that women's quality of life and levels of sexual satisfaction may be positively impacted by the training provided to lessen their symptoms, their follow-up, and their continuity. Additionally, it is anticipated that by encouraging better treatment compliance among women with OAB, hospital expenses will drop, which will benefit the national economy. In order to ascertain the impact of bladder training delivered via mobile application on quality of life and levels of sexual satisfaction in women with overactive bladder, this study was designed. Between February 2023 and June 2024, this randomized controlled experimental design study will be conducted in the urogynecology clinic of a university hospital on Istanbul's Anatolian side. The sample size was determined via G-Power power analysis, and the groups were chosen using basic randomization. There will be 100 women studied, 50 in the study group (WG) and 50 in the control group (KG), all of whom have been diagnosed with overactive bladder. Through the smartphone application, WG women will receive bladder training, as well as follow-up care. Data will be gathered using the Quality of Life Scale, Sexual Satisfaction Scale, Mobile Application Usage Scales (only mobile application group), and Collection Form, Follow-Up Form. In the third and sixth months, new data will be collected on the Quality of Life Scale, Sexual Satisfaction Scale, and Mobile Application Usage Scales (just for the Mobile Application Group). There will be a data analysis.

NCT ID: NCT05719285 Completed - Overactive Bladder Clinical Trials

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the outcomes of differing durations of antibiotic prophylaxis with bladder onabotulinumtoxinA injection in patients with refractory overactive bladder. The main question it aims to answer are: • Is the incidence of post-procedure UTI similar between single-dose and multi-day durations of peri-procedural antibiotics? Participants will be randomized to single-dose versus multi-day dose of antibiotic prophylaxis with bladder onabotulinumtoxinA injection. Researchers will compare incidence of UTI in each group to see if there is a significant difference.

NCT ID: NCT05572918 Not yet recruiting - Overactive Bladder Clinical Trials

Developing a Simple Test to Diagnose Overactive Bladder

Start date: December 1, 2022
Phase:
Study type: Observational

In order to develop a test to diagnose overactive bladder from urine, it is essential that this test is at least as accurate as the tools that clinicians currently use. As such, this study will compare the performance of the device in development to the performance of existing methods.

NCT ID: NCT05543382 Active, not recruiting - Clinical trials for Overactive Bladder Syndrome

Cycling Study With the Axonics System

Start date: August 9, 2022
Phase:
Study type: Observational [Patient Registry]

A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.

NCT ID: NCT05493748 Recruiting - Clinical trials for Overactive Bladder Syndrome

Virtual Bladder Training for Overactive Bladder Syndrome in Women. Which Symptom Responds Better?

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

According to International Urogynecological Association and International Continence Society joint report on the terminology for female pelvic floor dysfunction, overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. Bladder training lasting for a minimum of 4 to 6 weeks is indicated as a first-line treatment. The investigators' goal is to compare changes in satisfaction, measured in terms of quality of life, in 2 groups of women with different main accompanying symptoms in OAB (frequency vs. nocturia), before and after bladder training utilizing telemedicine (virtual bladder training), for 4 to 6 weeks.

NCT ID: NCT05313984 Completed - Fecal Incontinence Clinical Trials

OptiLUTS Part C: The Development of a Symptom Assessment Tool in Sacral Neuromodulation.

OptiLUTS
Start date: March 1, 2018
Phase:
Study type: Observational

Sacral neuromodulation (SNM) is a two-staged 2nd-line therapy for therapy-resistant LUTS and fecal incontinence. Currently, the assessment of symptoms at baseline and after stage I is directed towards a discipline related evaluation. The OptiLUTS trial strives for a more holistic approach, taking all pelvic floor dysfunctions into account. A holistic assessment tool will be developed and SNM-care pathway will be set-up.

NCT ID: NCT05309993 Recruiting - Overactive Bladder Clinical Trials

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

INTENSE
Start date: June 30, 2022
Phase: N/A
Study type: Interventional

The objective of this research is to perform a non-masked, non-inferiority randomized controlled trial to assess the quality of life (QOL) of women with idiopathic overactive bladder (OAB) before and after treatment with percutaneous tibial nerve stimulation (PTNS) or transcutaneous electrical nerve stimulation (TENS) of tibial nerve. The target population is patients with OAB who previously failed first- and second-line treatments and desire non-surgical management.

NCT ID: NCT05308979 Active, not recruiting - Overactive Bladder Clinical Trials

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

NCT ID: NCT05250245 Completed - Clinical trials for Obstructive Sleep Apnea

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

Start date: June 1, 2020
Phase: Phase 4
Study type: Interventional

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

NCT ID: NCT05221021 Recruiting - Clinical trials for Overactive Bladder Syndrome

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.